Please login to the form below

Not currently logged in
Email:
Password:

market share

This page shows the latest market share news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

Sun Pharma passes milestone with novel psoriasis drug approval

The company may find the going tough once it starts commercialising the drug however, as psoriasis therapy has seen a big increase in the number of drugs competing for market share ... For years treatment for patients requiring systemic therapy has been

Latest news

  • Novo Nordisk’s semaglutide obesity trial hits the mark Novo Nordisk’s semaglutide obesity trial hits the mark

    Novo has made no secret of its ambition in obesity and the potential of semaglutide to transform the largely unserved and under-penetrated weight loss market. ... drugmaker last year but is seeing its market share shrink thanks to new rivals such as Eli

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    BMS gets OK for monthly Opdivo dosing. Analysts predict the new dosing schedule could see the pharma giant win market share. ... According to analysts, the less frequent schedule could help BMS win market share as the use of checkpoint inhibitor

  • Gilead says switching studies back new HIV therapy Biktarvy Gilead says switching studies back new HIV therapy Biktarvy

    Triumeq is a key growth product for ViiV and parent GlaxoSmithKline (GSK), growing 42% to reach nearly £2.5bn (around $3.5bn) last year and spearheading a gain in HIV market ... share for ViiV, so Gilead will have to pull out all the stops to build

  • Merck/Pfizer’s cancer immunotherapy latecomer hits a snag Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

    Merck KGaA and Pfizer’s catch-up attempt in the checkpoint inhibitor market has hit a setback after their Bavencio drug failed a key lung cancer trial. ... jostling for market share with other entrants, namely Roche’s Tecentriq (atezolizumab) and

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    With four ALK inhibitors already jostling for market share in lung cancer, Pfizer’s entry to the category seems like it could face an uphill battle, although oncologists are now welcoming

More from news
Approximately 0 fully matching, plus 482 partially matching documents found.

Latest Intelligence

  • Market research

    Healthcare terms - Market research.

  • Marketing

    Healthcare terms - Marketing.

  • Market access

    Healthcare terms - Market access.

  • The good, the bad and the ugly The good, the bad and the ugly

    Canada. Nonetheless, new rival innovation in the anticoagulant market is already presenting challenges for Xarelto. ... Small factors like position to market, route of administration and dosing frequency will play a large role in deciding market share.”

  • The ‘Million Hour Challenge’ The ‘Million Hour Challenge’

    It is big and small at the same time.”. To help employees navigate to their starting point, the ‘3-steps to Simplification’training tool was developed, a portal to share their ... This encouraged employees to propose opportunities to eliminate

More from intelligence
Approximately 1 fully matching, plus 56 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics